Works by Ruijter, R.

Results: 7

Pegylated- l -asparaginase therapy for feline large cell lymphoma: 82 cases (2017–2020).
Published in:
Journal of Feline Medicine & Surgery, 2023, v. 25, n. 9, p. 1, doi. 10.1177/1098612X231193536
By:
- Bik, Céline A;
- Ruijter, Bart R;
- Van den Bossche, Lindsay;
- Teske, Erik;
- Niessen, Stijn JM;
- Forcada, Yaiza
Publication type:
Article
Pharmacokinetics of (hydrated)cisplatin and (di)mesan during a phase I study of BNP7787 and cisplatin in cancer patients.
Published in:
British Journal of Clinical Pharmacology, 2001, v. 51, n. 5, p. 504P
By:
- Verschraagen, M.;
- Boven, E.;
- Ruijter, R.;
- Westerman, M.;
- Hausheer, F.H.;
- Van Der Vijgh, W.J.F.
Publication type:
Article
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
Published in:
British Journal of Cancer, 2012, v. 106, n. 11, p. 1728, doi. 10.1038/bjc.2012.158
By:
- Kaye, S;
- Aamdal, S;
- Jones, R;
- Freyer, G;
- Pujade-Lauraine, E;
- de Vries, E G E;
- Barriuso, J;
- Sandhu, S;
- Tan, D S-W;
- Hartog, V;
- Kuenen, B;
- Ruijter, R;
- Kristensen, G B;
- Nyakas, M;
- Barrett, S;
- Burke, W;
- Pietersma, D;
- Stuart, M;
- Emeribe, U;
- Boven, E
Publication type:
Article
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
Published in:
British Journal of Cancer, 2005, v. 92, n. 9, p. 1636, doi. 10.1038/sj.bjc.6602553
By:
- Boven, E.;
- Westerman, M.;
- van Groeningen, C. J.;
- Verschraagen, M.;
- Ruijter, R.;
- Zegers, I.;
- van der Vijgh, W. J. F.;
- Giaccone, G.
Publication type:
Article
Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.
Published in:
2018
By:
- van Zweeden, A. A.;
- van Groeningen, C. J.;
- Honeywell, R. J.;
- Giovannetti, E.;
- Ruijter, R.;
- Smorenburg, C. H.;
- Giaccone, G.;
- Verheul, H. M. W.;
- Peters, G. J.;
- van der Vliet, Hans J.
Publication type:
journal article
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
Published in:
2011
By:
- Schöffski P;
- Dumez H;
- Ruijter R;
- Miguel-Lillo B;
- Soto-Matos A;
- Alfaro V;
- Giaccone G
Publication type:
Journal Article
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
Published in:
Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 6, p. 1397, doi. 10.1007/s00280-011-1612-1
By:
- Schöffski, P.;
- Dumez, H.;
- Ruijter, R.;
- Miguel-Lillo, B.;
- Soto-Matos, A.;
- Alfaro, V.;
- Giaccone, G.
Publication type:
Article

Works by Ruijter, R.

Pegylated- l -asparaginase therapy for feline large cell lymphoma: 82 cases (2017–2020).

Pharmacokinetics of (hydrated)cisplatin and (di)mesan during a phase I study of BNP7787 and cisplatin in cancer patients.

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.

Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.